Oncology Corporate Profile
Immunocore, headquartered in Abingdon, Oxfordshire, United Kingdom, is a privately owned, clinical-stage, biotechnology company discovering and developing highly innovative biotherapeutics known as ImmTACs for the treatment of cancer and a range of other serious diseases. Its world-leading proprietary T Cell Receptor (TCR) technology exploits the power of the body’s own immune system to find and kill diseased cells. Immunocore has established a robust technology platform which has yielded an ImmTAC clinical candidate, IMCgp100, currently in Phase I/II clinical trials in melanoma patients in both the US and UK.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|IMCgp100 (+ merestinib)||immunotherapy||Melanoma||I||Eli Lilly|
|IMCgp100 (+ durvalumab and tremelimumab )||immunotherapy||Melanoma||I||Eli Lilly|
|IMCgp100 (+ galunisertib)||immunotherapy||Melanoma||I||Eli Lilly|
View additional information on product candidates here »